A nasal spray that administers an attenuated coronavirus vaccine protects better against Covid-19 than the mRNA vaccination. At least, that is a conclusion reached by veterinarian Jakob Trimpert and his team after initial studies on animal models. Researchers from the Department of Veterinary Medicine and other institutions along with developers from the vaccine development company RocketVax are investigating whether it also works better in humans. The Patent and Licensing Service in the Research Division of Freie Universität is responsible for the legal protection of research findings as well as the use of the patents by third parties.

• Press release, “Nasal Vaccine to Prevent Covid-19 Passes First Tests”
• Patent and Licensing Service